Source: International Congress 2019 – Complex respiratory infections in clinical practice
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Kim (Seoul, Republic of Korea), Y. Kwon (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), O. Kim (Seoul, Republic of Korea), Y. Park (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea), Y. Chong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea). Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease. 4573

Member's Comments

No comment yet.

Related content which might interest you: Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020 Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018 Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019 Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections Year: 2009 The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002 Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017 Switch effects from daily to intermittent treatment with a daily regimen dosage for Mycobacterium avium complex pulmonary disease Source: International Congress 2019 – Clinical and translational studies of bronchiectasis and non-TB mycobacterial infection Year: 2019 Hospital-based antibiotic use in patients with Mycobacterium avium complex Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018 Year: 2018 Treatment of severe Mycobacterium avium complex pulmonary disease with a adjunctive amikacin and clofazimine versus standard regimen alone, a retrospective study Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I Year: 2019 Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 A double blind randomized study of aminoglycoside infusion with combined therapy for pulmonary mycobacterium avium complex disease Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis Year: 2006 The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017 Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016 The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019 Year: 2020 Effect of clarithromycin alone and clarithromycin containing regimen for mycobacteriun avium complex pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 558s Year: 2006 Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009 Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022